Status:

COMPLETED

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Lead Sponsor:

AstraZeneca

Conditions:

NSAIDs

Upper GI Symptoms

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study was a multicentre, double-blind, randomised, placebo-controlled parallel group study consisting of 4 visits over a period of 6 months. The primary variable was to assess theefficacy of esom...

Eligibility Criteria

Inclusion

  • Signed informed consent.
  • Completed the SH-NEN-0003 study with relief of upper GI symptom. Relief is defined as "last 7 days with a diary assessment of None or Minimal, but allowing up to 2 days to be rated as Mild during the 7-day period".
  • A clinical diagnosis of a chronic condition (e.g., osteoarthritis or rheumatoid arthritis) that requires continuous daily NSAID treatment for at least 6 months. Daily NSAID treatment is defined as taking the prescribed dose for at least 5 of 7 days in any given week and can include COX-2 selective NSAIDs, multiple NSAIDs, and high-dose NSAIDs.
  • Daily NSAID treatment dose and type:
  • Must have been stable for at least 9 weeks prior to inclusion
  • Are expected to remain stable for the duration of the study.
  • Must be administered orally. If more than one type of NSAID treatment is used, at least one type must be administered orally.
  • Hp negative on Histology performed at baseline endoscopy in the study SHNEN-0003.

Exclusion

  • Discontinuation from study SH-NEN-0003
  • Pain, discomfort or burning in the upper abdomen precipitated by exercise or relieved by defecation.
  • Pain, discomfort or burning in the upper abdomen not associated with the use of NSAIDs, including COX-2 selective NSAIDs.
  • Pregnancy or lactation. Women of childbearing potential must maintain effective contraception during the study period as judged by the investigator.

Key Trial Info

Start Date :

April 1 2001

Trial Type :

INTERVENTIONAL

End Date :

February 1 2003

Estimated Enrollment :

276 Patients enrolled

Trial Details

Trial ID

NCT00241553

Start Date

April 1 2001

End Date

February 1 2003

Last Update

January 24 2011

Active Locations (136)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 34 (136 locations)

1

Research Site

Tallassee, Alabama, United States

2

Research Site

Phoenix, Arizona, United States

3

Research Site

Garden Grove, California, United States

4

Research Site

Orange, California, United States